THE TAPE
IRMD · Medical Instruments · $1.1B

iRadimed Corporation

$84.84▼ −0.60%
Last close
Relative strength
38RS
of 99, against every stock▼ -10 on the month
Falling back
Strong industry, weak stock
−27.0%
six months against Medical Instruments
52-week range
−21.4%
from the high
$76.35$107.90
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +14% on a year ago
Why it is on no screen

IRMD is off the screens on one check: relative strength.

A base has formed18.8 weeks, from 76.35 to 102.99.
Long enough to count18.8 weeks against 3 needed.
Shallow enough25.9% deep against 35% allowed.
Close to its pivot-17.6% from the pivot; listed down to -20%.
Relative strengthRS 38 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$81.47
-4.0% · tested 3× · last 40 sessions ago
Resistance above
$88.26
+4.0% · tested 15× · last 2 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

iRadimed Corporation is not on any of the screens right now. Its relative strength rating is 38, and it sits in Medical Instruments.

Against its industry
Strong industry, weak stockBehind its industry over one and six months while the industry is fully aligned and ahead of the S&P 500.
One month against its industry
-7.7%
Three months against its industry
-3.3%
Six months against its industry
-27.0%

Read against an equal-weighted index of Medical Instruments, which is +31.0% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 8.5% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$89.3M
+14.2% year on year
Operating margin
32.3%
gross 75.5%
Net margin
26.8%
Free cash flow
$26.1M
2.4% of market cap
Price to sales
12.1×
Price to earnings
45.2×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 30
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$24.2M
+18.3% QoQ · +14.2% YoY
Gross margin
76.3%
+2.2 pts QoQ
Net income
$6.5M
Positive
Free cash flow
$6.9M
Cash generating

What the numbers say

  • Revenue +14.2% year over year, +18.3% on the quarter
  • Good: Gross margin 76.3%, +2.2 points on the quarter
  • Good: Profitable: net income $7M, operating margin 33.6%
  • Good: Cash generating: operating cash flow $7M, free cash flow $7M
  • Good: Net cash $63M · cash $63M
Revenue by quarter
Free cash flow
Net income
shares +0.1% in a year · net cash $63.3M

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-05
+9.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Reported resultsFiling · 2026-10-31
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
GappedTape · 2026-10-31
-10.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-10-31
-10.6% on earnings 2026-10-30
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Earnings comingEvent · 2026-10-29
reports 2026-10-30 bmo
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Earnings date movedEvent · 2026-10-28
2026-10-29 -> 2026-10-30
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Earnings date movedEvent · 2026-10-21
2026-11-02 -> 2026-10-29
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Earnings date movedEvent · 2026-10-20
2026-10-29 -> 2026-11-02
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news

No headlines for this company in the last couple of weeks.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect
Strong buy0
Buy2
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
iRadimed Corporation (IRMD) — The Tape